Monographie - Cyclophosphamide

Τελευταία ενημέρωση :
19/11/2024

Cyclophosphamide

χημική δομή

Εμπορική ονομασία

Οι εμπορικές ονομασίες είναι ενδεικτικές και η σύνθεση των εκδόχων μπορεί να διαφέρει ανάλογα με τη χώρα και τα εργαστήρια

Alkyloxan	Αίγυπτος, Μαλαισία
Celomide	Ινδία
Ciclofosfamida	Αργεντινή, Ρουμανία, Χιλή
Cicloxal	Ισπανία
Cryofaxol	Μεξικό
Cycloblastin	Αυστραλία
Cycloblastine	Ολλανδία
Cyclophosphamid	Γερμανία, Δανία
Cyclophosphamide	Η.Π.Α., Μεγάλη Βρετανία, νέα Ζηλανδία, Σαουδική Αραβία
Cyclostin	Γερμανία
Cycloxan	Μαλαισία
Cycram	Αίγυπτος
Cytoxan	Η.Π.Α., Καναδάς, Ουγγαρία
Eldamide	Ινδία
Endoxan	Yhdistyneet arabiemiirikunnat, Αυστραλία, Αυστρία, Βέλγιο, Βενεζουέλα, Γαλλία, Γερμανία, Εκουαδόρ, Ελβετία, Ελλάδα, Ινδία, Ιράν, Ιταλία, Κολομβία, Κροατία, Λουξεμβούργο, Μαρόκο, νέα Ζηλανδία, Ολλανδία, Ουγγαρία, Πολωνία, Πορτογαλία, Σαουδική Αραβία, Σλοβενία, Ταϊλάνδη, Τουρκία, Τυνησία, Χιλή
Endoxana	Ιρλανδία, Μεγάλη Βρετανία
Formitex	Κολομβία, Μεξικό
Genoxal	Ισπανία
Genuxal	Βραζιλία
Hidrofosmin	Μεξικό
Ledoxan	Κολομβία
Ledoxina	Κολομβία, Μεξικό
Neophos	Αίγυπτος
Neosar	Η.Π.Α.
Procytox	Καναδάς
Sendoxan	Δανία, Ισλανδία, Νορβηγία, Σουηδία, Φινλανδία
Syklofosfamid	Τουρκία, Φινλανδία

Βιβλιογραφία : Cyclophosphamide

	τύπος	δημοσίευση
3	εφημερίδα	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
40	εφημερίδα	Dine T, Lebegue S, Benaji B, Gressier B, Segard V, Goudaliez F, Luyckx M, Brunet C, Mallevais ML, Kablan J, Cazin M, Cazin JC. Stability and compatibility studies of four cytostatic agents (fluorouracil, dacarbazine, cyclophosphamide and ifosfamide) with PVC infusion bags. Pharm Sci Communications 1994 ; 4: 97-101.
50	εφημερίδα	Fleming RA, Olsen DJ, Savage PD, Fox JL. Stability of ondansetron hydrochloride and cyclophosphamide in injectable solutions. Am J Health-Syst Pharm 1995 ; 52: 514-516.
57	εφημερίδα	Mayron D, Gennaro AR. Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs. Am J Health-Syst Pharm 1996 ; 53: 294-304.
81	εφημερίδα	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	εφημερίδα	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
85	εφημερίδα	Trissel LA, Bready BB. Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 1716-1719.
91	εφημερίδα	Lober CA, Dollard PA. Visual compatibility of gallium nitrate with selected drugs during Y-site injection. Am J Hosp Pharm 1993 ; 50: 1208-1210.
99	εφημερίδα	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
150	εφημερίδα	Aujoulat P, Coze C, Braguer D, Raybaud C. Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens. J Pharm Clin 1993 ; 12: 31-35.
169	εφημερίδα	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
170	εφημερίδα	Brooke D, Scott JA, Bequette RJ. Effect of briefly heating cyclophosphamide solutions. Am J Hosp Pharm 1975 ; 62: 44-45.
172	εφημερίδα	Beijnen JH, van Gijn R, Challa EE, Kaijser GP, Underberg WJM. Chemical stability of two sterile, parenteral formulations of cyclophosphamide (Endoxan) after reconstitution and dilution in commonly used infusion fluids. J Parenter Sci Technol 1992 ; 46: 111-116.
244	εφημερίδα	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	εφημερίδα	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	εφημερίδα	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
300	εφημερίδα	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	εφημερίδα	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	εφημερίδα	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
331	εφημερίδα	Marquardt ED. Visual compatibility of hydroxyzine hydrochloride with various antineoplasic agents. Am J Hosp Pharm 1988 ; 45: 2127.
334	εφημερίδα	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	εφημερίδα	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
491	εφημερίδα	Turowski RC, Durthaler JM. Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2181-2184.
492	εφημερίδα	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
660	εφημερίδα	Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232.
905	εφημερίδα	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	εφημερίδα	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1026	εφημερίδα	Mayron D, Gennaro AR. Stability and compatibility of topotecan hydrochloride with selected drugs. Am J Health-Syst Pharm 1999 ; 56: 875-881.
1410	εφημερίδα	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	εφημερίδα	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	εφημερίδα	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1496	εφημερίδα	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.
1520	Εργαστήριο	Etude de stabilité des médicaments en Ecoflac® B Braun 2001
1625	εφημερίδα	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1662	εφημερίδα	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1728	εφημερίδα	Mittner A, Vincze Z, Jemnitz. Stability of cyclophosphamide containing infusions. Pharmazie 1999 ; 54: 224-225.
1833	εφημερίδα	Menard C, Bourguignon C, Schlatter J, Vermerie N. Stability of cyclophosphamide and mesna admixtures in polyethylene infusion bags. Ann Pharmacotherapy 2003 ; 37, 12: 1789-1792.
1925	εφημερίδα	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1953	εφημερίδα	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982	εφημερίδα	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2016	εφημερίδα	Xu QA, Trissel LA. Compatibility of palonosetron with cyclophosphamide and with ifosfamide during Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 1998-2000.
2104	εφημερίδα	Iriarte Izura MA, Gozalo garcia MJ, Marcotegui Ros F, Nagore Indurain C, Urdaniz Baztan AO. Estudio de la estabilidad de mezclas ciclofosfamida/mesna e ifosfamida/mesna en soluciones intravenosas de gran volumen. Farm Hosp 2000 ; 24: 145-150
2262	εφημερίδα	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
3128	Εργαστήριο	Mitomycine (Amétycine®) - Résumé Caractéristiques du Produit Prostrakan 2013
3574	Εργαστήριο	Ondansetron - Résumé des caractéristiques du produit Accord Healthcare France SAS 2013
4471	Εργαστήριο	Amétycine 10 mg poudre pour solution injectable - Résumé des caractéristiques du produit - Oct 10, 2019 Kyowa Kirin Pharma 2019

Mentions Légales